Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is the parent company of a newly created private equity subsidiary called Algernon NeuroScience, that is advancing a program investigating a proprietary form of DMT for stroke and traumatic brain injury (TBI). The Company recently closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 Ifenprodil research program to treat chronic cough and idiopathic pulmonary fibrosis, and also maintains a research program for chronic kidney disease.
Company Profile
Latest Presentation
Corporate Fact Sheet
View Corporate Fact SheetIndustry Classifications
Sector:
Biotechnology
Industry:
Drug Development
NAICS:
Research and Development in the Physical, Engineering, and Life Sciences (541710)
SIC:
Commercial Physical and Biological Research (8731)
Contact Information
Investor Relations
Christopher J. Moreau
Chief Executive Officer
T: 604-398-4175
chris@algernonpharmaceuticals.com
Company Contact
Algernon Pharmaceuticals Inc.
601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
Canada
T: 604-398-4175
info@algernonpharmaceuticals.com
